The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Recent advances in imaging and the approval of ...
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
WALTHAM, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company and leader in complement, today announced that the company has received ...
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study ...
Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic atrophy market is a tough nut to crack. Syfovre—which became the first ...
Dec. 16, 2022 7:00 AM ETApellis Pharmaceuticals, Inc. (APLS) WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS), a global biopharmaceutical company and leader in ...
Apellis Pharmaceuticals, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from geographic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback